ReviewEndocrinology and metabolism (Seoul, Korea)2015
Mutation Profile of Well-Differentiated Thyroid Cancer in Asians.
Review in Endocrinology and metabolism (Seoul, Korea), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Size Increment During Surveillance in Papillary Thyroid Cancer: Evidence Synthesis and Dose-Response Meta-Analysis.Cancer reports (Hoboken, N.J.) · 2025Pooled it
- Risk and Prognostic Factors for BRAFBioMed research international · 2022Pooled it
- Mutation-specific dynamics of dedifferentiation trajectories and tumor-stromal interactions in thyroid cancer.Molecular cancer · 2026Article
- Pathology-guided enrichment of targetable gene rearrangements in BRAF wild-type papillary thyroid carcinoma.Scientific reports · 2026Article
- Somatostatin receptor expression for peptide receptor radionuclide therapy in Japanese patients with recurrent or metastatic differentiated thyroid cancer.Annals of nuclear medicine · 2026Article
- Can mutation abundance assess the biological behavior of BRAFJournal of translational medicine · 2025Article
- Molecular Markers in Follicular and Oncocytic Thyroid Carcinomas: Clinical Application of Molecular Genetic Testing.Current oncology (Toronto, Ont.) · 2024Article
- Analysis of Urinary Iodine Concentration in Differentiated Thyroid Cancer and Breast Cancer Cases.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Toward Systems-Level Metabolic Analysis in Endocrine Disorders and Cancer.Endocrinology and metabolism (Seoul, Korea) · 2023Review
- Long-Term Changes in the Mortality Rates of Thyroid Cancer in Korea: Analysis of Korean National Data from 1985 to 2020.Endocrinology and metabolism (Seoul, Korea) · 2023Article
- Article
- Primary small cell thyroid carcinoma combined with poorly differentiated thyroid carcinoma, evidence for a common origin: A case report.Oncology letters · 2023Article
- Histological and Genetic Diversity in Ovarian Mucinous Carcinomas: A Pilot Study.Current oncology (Toronto, Ont.) · 2023Article
- The Association of Socioeconomic Factors and Well-Differentiated Thyroid Cancer.The Journal of surgical research · 2023Article
- BRAFWorld journal of surgical oncology · 2023Review
- Exploring the correlation analysis of immune microenvironment, mutation burden and prognosis of papillary thyroid carcinoma based on Estimate algorithm.Gland surgery · 2022Article
- Molecular pathogenesis of pediatric thyroid carcinoma.Journal of radiation research · 2021Review
- Association of Hyperparathyroidism and Papillary Thyroid Cancer: A Multicenter Retrospective Study (Endocrinol Metab 2020;35:925-32, Chaiho Jeong et al.).Endocrinology and metabolism (Seoul, Korea) · 2021Article
- Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer.Endocrinology and metabolism (Seoul, Korea) · 2021Article
- The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, andOncoTargets and therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in molecular diagnostics have led to significant insights into the genetic basis of thyroid tumorigenesis. Among the mutations commonly seen in thyroid cancers, the vast majority are associated with the mitogen-activated protein kinase pathway. B-Raf proto-oncogene (BRAF) mutations are the most common mutations observed in papillary thyroid cancers (PTCs), followed by RET/PTC rearrangements and RAS mutations, while follicular thyroid cancers are more likely to harbor RAS mutations or PAX8/peroxisome proliferator-activated receptor γ (PPARγ) rearrangements. Beyond these more common mutations, alterations in the telomerase reverse transcriptase (TERT) promoter have recently been associated with clinicopathologic features, disease prognosis, and tumorigenesis in thyroid cancer. While the mutations underlying thyroid tumorigenesis are well known, the frequency of these mutations is strongly associated with geography, with clear differences reported between Asian and Western countries. Of particular interest is the prevalence of BRAF mutations, with Korean patients exhibiting the highest rate of BRAF-associated thyroid cancers in the world. Here, we review the prevalence of each of the most common mutations in Asian and Western countries, and identify the characteristics of well-differentiated thyroid cancer in Asians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.